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Featured Oral Session...Vascular Access 
and Vascular Closure Devices
Monday, March 08, 2004, 2:00 p.m.-3:30 p.m.
Morial Convention Center, Room 243
2:15 p.m.
818-2 Vascular Access and Fluoroscopy in Percutaneous 
Coronary Interventions: A Quality Improvement Project
Peter VerLee, Patricia Hofmaster, Theodore Silver, Paul Vom Eigen, Matthew Rowe, 
Carol Gallupe, Winthrop Piper, David Malenka, Eastern Maine Medical Center, Bangor, 
ME, Dartmouth-Hitchcock Medical Center, Lebanon, NH
Background: In previous work by the Northern New England Cardiovascular Study
Group risk factors for vascular access site complications in PCI were identified and a
region-wide effort to reduce these complications was initiated. As part of this effort we
considered making a regional recommendation that location of the femoral head as seen
on fluoroscopy (fluoro) be used to help determine the site of femoral artery puncture. To
assess the validity of such a practice guideline we assessed the use of fluoro guided vas-
cular access to determine whether it reduced the rate of vascular complications and
shortened length of stay.
Methods: Data was collected prospectively on 2,206 consecutive PCIs at Eastern Maine
Medical Center from 1999-2002 including use of fluoro, vascular access site complica-
tions (bleeding, pseudoaneurysm formation, hematoma, embolic event or thrombus, A-V
fistula), and length of stay.
Results: Use of fluoro among 7 interventionists was variable: 2 >20%, 3 35-45%, 2
>70%. Among all interventions, 46% were performed with fluoro to guide vascular
access. The use of fluoro was associated with a significantly lower incidence of artery
injury (0.59% v 1.51%, p=0.04. Among a subset of physicians (n=3) whose use of fluoro
was less frequent and variable (38%, 39%, 45%), there were fewer vascular injuries
among patients for whom fluoro guided vascular access (0.71% v 1.77%, p=0.14). Aver-
age length of stay was significantly lower among patients in the fluoro group ( 2.1 days
vs. 2.6, p=0.007).
Conclusion: We conclude that using fluoro to guide vascular access leads to lower com-
plication rates and a shorter length of stay and that this approach to femoral access
might reasonably become a regional standard of care. At Eastern Maine Medical Center
the current use of fluoro to guide vascular access now exceeds 70%.
2:30 p.m.
818-3 Declining Entry Site Complications After Percutaneous 
Coronary Interventions
Joseph Lindsay, Daniel A. Canos, Ellen Pinnow, Sue Apple, Peter C. Iloanya, Augusto D. 
Pichard, Washington Hospital Center, Washington, DC
Background: Outcomes of percutaneous coronary intervention (PCI) have improved
over the past decade. Angiographic success is now > 95% and urgent/emergent coro-
nary revascularization surgery <1%. These advances are due to operator experience,
new equipment, and the adoption of more effective antithrombotic strategies. Ineffective
or dangerous devices and anticoagulation strategies have been abandoned. Little infor-
mation is available about the effect of these changes on entry-site complications. Meth-
ods:We examined entry-site complications in 14,194 pts with PCI from 1991-2001 in our
laboratoy. The frequency of surgical repair (SR) and major bleeding, (drop in hematocrit
of >0.15) were the outcomes of interest. Results: The frequency of major bleeding
steadily decreased (7.6% in 1991 to 1.5% in 2001 (p for trend <0.001). This decline was
paralleled by a reduction in the need for SR (4.5% in 1993 to 1.2% in 2001, p for trend
<0.001). Declining use of warfarin anticoagulation, lower target ACT levels for heparin
dosing, and less frequent use of an intra-aortic balloon pump (IABP) likely helped reduce
the frequency of these events. The introduction of GP IIb/IIIa inhibitors (currently used in
50% of cases) and the potent antiplatelet agents (current use 96%) did not interrupt the
decline. Conclusions: In this single center experience the improved procedural out-
comes of PCI have been accompanied by a dramatic reduction in entry site complica-
tions. 
2:45 p.m.
818-4 Vascular Complications Associated With Arteriotomy 
Closure Devices in Patients Undergoing Percutaneous 
Coronary Procedures: A Meta-Analysis
Eugenia Nikolsky, Amir Halkin, Roxana Mehran, Shoshana R. Krieger, Eve A. Aymong, 
Zoran Lasic, Manuela Negoita, Ramez Sulaiman, Ricardo A. Costa, Jeffrey W. Moses, 
Gregg W. Stone, Martin B. Leon, George D. Dangas, The Cardiovascular Research 
Foundation and the Lenox Hill Heart and Vascular Institute, New York, NY
Background. Arteriotomy closure devices (ACD) are frequently used for hemostasis after
percutaneous endovascular procedures. To evaluate overall vascular complications asso-
ciated with ACD, we performed a meta-analysis of studies using ACD in pts undergoing
percutaneous transfemoral coronary procedures. Methods. Studies considered for meta-
analysis included randomized, case-control and cohort studies comparing vascular com-
plications in pts managed with ACD (AngioSeal, VasoSeal and Perclose) vs. mechanical
compression. Cumulative incidence of major vascular complications was the primary
endpoint defined as pseudoaneurysm, a-v fistula, retroperitoneal hematoma, femoral
artery thrombosis, surgical vascular repair, access site infection, and transfusion. Data
on diagnostic catheterization (Dx) and percutaneous coronary interventions (PCI) were
assessed separately and in combination. Heterogeneity between studies was assessed
using Cochran’s Q-statistic. Results. A total of 30 studies involving 42,253 pts fulfilled the
inclusion criteria. Comparing complication rates with ACD vs. mechanical compression is
shown in the Figure. Conclusions. In the setting of Dx angiography the risk of complica-
tions was similar with all 3 devices compared to mechanical compression. In the setting
of PCI, risk of vascular complications using AngioSeal and Perclose was similar to that of
mechanical compression while complications appeared higher with VasoSeal compared
to mechanical compression.
Best Versus Worst Versus Core QCA
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Stent A 
Best
5.2±4.8%*¥ 17.6±10.9*§¥ 1/13(8%)*§¥ 0.43±0.81*§¥
Stent A 
Worst
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Stent A 
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11.5±4.8% 38.2±20.7% 4/13 (31%) 1.04±0.45
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18.7±11.3%§ 53.8±19.7%§ 8/13 (62%)§ 0.76±0.62§
Stent C 
Core
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All Stents 
Best
2.6%±0.7%*§ 11.3±10.6%*§ 0/39 (0%)*§ -0.49±0.72*§
All Stents 
Worst
37.9±18.1%§ 57.16±16.7%§ 29/39 (74%)§ 1.67±0.78§
All Stents 
Core
9.2±7% 31.6±7.4% 7/39 (18%) 0.67±0.61
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818-5 Percutaneous Transfemoral Coronary and Peripheral 
Procedures via Aortofemoral Synthetic Vascular Grafts: 
A Review of 123 Diagnostic and Interventional Cases
Michael J. Gallagher, Simon R. Dixon, Mohan C. Madala, Renny Abraham, Steven D. 
Rimar, William W. O'Neill, Joel K. Kahn, William Beaumont Hospital, Royal Oak, MI
Background: Few data exist regarding the incidence of vascular complications associ-
ated with transfemoral catheterization and sheath placement into synthetic vascular
grafts.
Methods: We performed a retrospective analysis of all patients who underwent
aortofemoral bypass surgery at our institution between January, 1991 and July, 2003.
Those patients who underwent subsequent transfemoral catheterization were selected. A
total of 123 procedures were performed in 70 patients between February, 1994 and April,
2003.
Results: One hundred and thirteen coronary (91.9%) and 10 peripheral (8.1%) proce-
dures were performed, including sixty-four (52.0%) interventional (angioplasty and/or
stent), and 59 (48%) diagnostic procedures. Two of the interventional procedures
included placement of an intraaortic balloon pump via the graft. The interval between
graft implantation and sheath placement was 2.9 + 2.1 years (range 4 days to 10.3
years). Four procedures (3.3%) required concomitant brachial or radial access due to
inability to access the ascending aorta via the femoral approach. Pre-procedural antico-
agulation included aspirin (91.9%), clopidogrel (28.5%), warfarin (10.6%), and intrave-
nous heparin (39.0%). The peak activated clotting time was 313 + 89 seconds. The
procedure time was 53.2 + 34.1 minutes, and sheaths were pulled an average of 5.2
hours after catheterization. Adverse events related to vascular access occurred in 8/123
(6.5%) procedures. Complications included blood transfusion (4.1%), thrombotic occlu-
sion (1.6%), and retroperitoneal bleed (0.8%). The two cases of thrombotic occlusion
were associated with early clinical signs of diminished perfusion. One patient required
surgical thrombectomy and the other was treated with intraarterial local thrombolysis.
There were no cases of graft infection or pseudoaneurysm formation, nor any deaths
attributable to vascular access complications.
Conclusion: Transfemoral sheath entry into a synthetic aortofemoral bypass graft is
associated with a low incidence of adverse vascular events. However, careful observation
and follow up during the 24-hour post catheterization period is critical.
3:15 p.m.
818-6 Women Remain at Higher Risk for Retroperitoneal 
Hematoma After Percutaneous Coronary Intervention in 
the Era of Glycoprotein IIb/IIIa Inhibitors and Vascular 
Closure Devices
H M Omar Farouque, Jennifer A. Tremmel, Meenakshi Aggarwal, Farshad Raissi 
Shabari, William F. Fearon, Mehrdad Rezaee, Alan C. Yeung, David P. Lee, Stanford 
University Medical Center, Stanford, CA
Background: The incidence, clinical features, and determinants of retroperitoneal
hematoma (RPH) after percutaneous coronary intervention (PCI) have been previously
described. We examined these variables in the current era of widespread glycoprotein
(GP) IIb/IIIa inhibitors and vascular closure devices (VCDs).
Methods: 3,230 PCI procedures were performed from January 2000 to August 2003.
There were 22 cases of radiographically documented RPH. Cases were compared to a
random sample of 50 controls using chi-square and logistic regression.
Results: The incidence of RPH was 6.8/1000 cases. Mean age±SD was 67±12 years in
both groups. Cases and controls did not differ in prevalence of hypertension, diabetes, or
hyperlipidemia. Median time from procedure end to onset of clinical signs was 126 min-
utes (range 15-840). Symptoms included lower abdominal pain (59%), diaphoresis
(59%), groin pain (45%), and back pain (18%). Groin hematoma was evident in 32%.
Hypotension occurred in 91%, with a mean BP nadir of 78/40 mmHg. Bradycardia requir-
ing atropine occurred in 36%. Hematocrit dropped from 37.5±3.4% to 27.1±3.8%
(p=0.007). All cases had blood loss anemia and at least two of the above clinical fea-
tures. Mean hospital stay was longer in RPH cases (2.2±1.3 vs. 1.7±1.5 days, p=0.06).
The use of GP IIb/IIIa inhibitors and the method of vascular closure had no effect on the
risk of RPH. There was also no association between RPH and acuity of PCI (elective vs.
emergent), duration of procedure, heparin dose, ACT level, arterial sheath size, insertion
of a venous sheath, or prior femoral artery puncture. Female sex was most strongly asso-
ciated with RPH (OR 5.0, 95% CI 1.7-14.5). Angiographic analysis revealed that a higher
femoral artery puncture in relation to the femoral head (superior third of the femoral head
and higher vs. mid third and lower) was also associated with RPH (OR 4.2, 95% CI 1.3-
14.0).
Conclusion: With the widespread use of GP IIb/IIIa inhibitors and VCDs, being a woman
remains a significant risk factor for RPH, as does a more superior femoral artery punc-
ture. Awareness of the determinants and clinical features of RPH may aid in prevention,
early recognition, and prompt treatment.
POSTER SESSION
1100 
Percutaneous Intervention: 
Pharmacologic and Biologic Adjuncts
Monday, March 08, 2004, 3:00 p.m.-5:00 p.m.
Morial Convention Center, Hall G
Presentation Hour: 3:00 p.m.-4:00 p.m.
1100-55 Intravenous Mesenchymal Stem Cell Therapy Early 
After Reperfused Acute Myocardial Infarction Improves 
Left Ventricular Function and Alters Ventricular 
Electrophysiologic Properties
Matthew J. Price, Chung-Chuan Chou, Malka Frantzen, Takashi Miyamoto, Saibal Kar, 
Dougal McClean, Suzhen Guo, Steve Lee, Prediman K. Shah, Bradley J. Martin, Michael 
Lill, James S. Forrester, Peng-Sheng Chen, Raj R. Makkar, Cedars Sinai Medical Center, 
Los Angeles, CA
Background: Direct intramyocardial injection of stem cells improves LV function. How-
ever, the injection of immature cells has been associated with an increased risk of ven-
tricular arrhythmia. We hypothesized that the IV infusion of allogeneic mesenchymal
stem cells (MSCs) without immunosuppresion after acute MI would improve LV function
but might be accompanied by pro-arrhythmic electrical remodeling.
Methods: An apical MI was induced in swine by balloon occlusion-reperfusion of the
mid-LAD. Animals received either no treatment, or, 30 minutes after reperfusion, DiI-
labeled allogeneic bone marrow derived MSCs (3.2±0.4 x 108 cells) were infused IV. LV
function was evaluated by LV cineangiography and wall thickness by echocardiography.
Epicardial effective refractory periods (ERPs) were determined at 3 month sacrifice.
Spectral imaging by confocal microscopy was used to identify Di-I in tissue specimens.
Results: At 3 months, MSC treated pigs [n=7] had significantly higher LVEF than con-
trols [n=8] (50±1% vs 44±1%, p=0.015), as well as significantly higher LV systolic pres-
sure (144±5 mmHg vs. 119±5 mmHg, p=0.01). The mean increase in LVEDV over time
tended to be greater in the control group (48+6cm3 vs.32+6cm3, p=0.09). The wall thick-
ness of normal, non-infarcted myocardium increased significantly more in controls than in
treated animals. ERPs of the MSC group were significantly shorter than controls at all
pacing cycle lengths in LV peri-infarct, LV free wall (FW), and right ventricular (RV) FW
(225+6, 227+5, 225+6 ms, vs 251+6, 251+6, 247+7 ms, all p<=0.002). The mean slope
of the ERP restitution curves was steeper in the MSC group than in controls (1.6±0.8 vs
1.0±0.4, p=0.02). DiI was identified in the lungs and myocardium of treated animals.
Conclusions: IV infusion of MSCs soon after reperfused acute MI in swine improves LV
function, lessens compensatory hypertrophy of non-infarcted myocardium, shortens ERP,
and steepens the ERP restitution curve. Clinical trials assessing the efficacy of IV MSC
therapy after MI in humans should include arrhythmia monitoring.
1100-56 Comparison Between Intracoronary Infusion and Direct 
Transendocardial Injection of Mesenchymal Stem Cells 
in a Dog Acute Ischemia Model
Emerson C. Perin, Joao A. Assad, Guilherme V. Silva, Stephanie Coulter, Judy Ober, 
Jing Lin, Andre L. Sousa, Silvio Litowski, Yong Geng, Bradley J. Martin, William K. 
Vaughn, James T. Willerson, Texas Heart Institute, Houston, TX
Background: Experimental data suggest that mesencymal stem cell (MSC) therapy con-
tributes to healing after acute myocardial infarction(AMI). The ideal route of administra-
tion is still contrversial.
Methods: A total of 10 dogs were divided in three groups:a)Control n=3; b)Intracoronary
(IC) n=3 and c) NOGA guided transendocardial injections (TEI) n=4. All animals had an
anterior wall AMI induced by ligation of LAD artery for three hours and then reperfused.
The animals received cell therapy (100 million MSC's(Osiris)) 1 wk after AMI and were
sacrificed 2 wks after cell therapy. 2D-echo was performed immediately before AMI, cell
therapy and sacrifice. NOGA mapping was performed immediately before cell therapy
and sacrifice. Ischemic area was measured by NOGA. ANOVA was performed.
Results: The 2D-echo findings concerning ejection fraction (EF), end-diastolic dimension
(EDD), end-systolic dimension (ESD), and ischemic area are presented in table 1. The
TEI group had a statistically significant increase in EF (p=0.006), a reduction in
EDD(p=0.04), a reduction in ESD (p=0.02), and more importantly a reduction in ischemic
area (p=0.006) when compared to the control group. All the other comparisons did not
reach statistical significance (p>0.05).
